Katja Fechner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katja Fechner has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
Dorit Di Gioia
Department of Medicine III, LMU University Hospital, Munich, Germany
3 shared publications- Robert Grützmann
Department of Surgery, University Hospital Erlangen, 91054 Erlangen, Germany
3 shared publications - Abbas Agaimy
Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany
2 shared publications - Axel Denz
Department of General and Visceral Surgery, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Krankenhausstraße 12, 91054 Erlangen, Germany
2 shared publications - Lars Hartwin Lindner
Department of Medicine III, LMU University Hospital, Munich, Germany
2 shared publications - Luc M. Berclaz
Department of Medicine III, LMU University Hospital, Munich, Germany
2 shared publications
Latest Publications
- Open Access
Matched primary-metastasis single-nucleus and spatial profiling of leiomyosarcoma identifies antigen-presenting fibroblasts at the tumor-organ interface
Leiomyosarcoma is an aggressive soft tissue sarcoma that metastasizes preferentially to lung and liver. Because matched primary and metastatic specimens are rarely available, the cellular changes that accompany metastatic progression remain poorly defined. Here we combined single-nucleus RNA sequencing of archival FFPE tissue from four matched primary-metastasis pairs (two lung, two liver metastases; 48,941 nuclei) with imaging-based spatial transcriptomics of an extended tissue microarray cohort of 21 patients (69 cores, 313,218 cells). Malignant cells, not assignable from transcriptomic references alone, were defined by inferred copy number profiles that were concordant with matched DNA methylation arrays and confirmed the clonal origin of each metastasis. Malignant metaprograms were organ-associated, with a stress- and hypoxia-associated program enriched in lung metastases and a proliferative, matrix-remodeling program enriched in liver metastases. Antigen-presenting cancer-associated fibroblasts (apCAFs) were enriched in metastases relative to matched primaries. This shift was reproduced in the spatial cohort (p = 0.001), where apCAFs formed a discrete band at the tumor-organ interface between malignant cells and adjacent parenchyma, whereas they were sparse and randomly distributed in primary tumors. Spatial transcriptomics further resolved the malignant compartment into three histomolecular phenotypes: (i) smooth-muscle-like with myxoid features, (ii) GPNMB⁺ with anaplastic features, and (iii) PDGFRB⁺ with vessel-rich stroma, each with a concordant immunohistochemical (α-SMA, GPNMB, PDGFRB) and morphological correlate. Together, our data provide a matched primary-metastasis reference for leiomyosarcoma, identify apCAFs as a spatially organized, metastasis-associated stromal population, and delineate histomolecular phenotypes recognizable by routine immunohistochemistry, including a GPNMB⁺ phenotype potentially amenable to GPNMB-directed therapies.
Open AccessMatched primary-metastasis single-nucleus and spatial profiling of leiomyosarcoma identifies antigen-presenting fibroblasts at the tumor-organ interface
Leiomyosarcoma is an aggressive soft tissue sarcoma that metastasizes preferentially to lung and liver. Because matched primary and metastatic specimens are rarely available, the cellular changes that accompany metastatic progression remain poorly defined. Here we combined single-nucleus RNA sequencing of archival FFPE tissue from four matched primary-metastasis pairs (two lung, two liver metastases; 48,941 nuclei) with imaging-based spatial transcriptomics of an extended tissue microarray cohort of 21 patients (69 cores, 313,218 cells). Malignant cells, not assignable from transcriptomic references alone, were defined by inferred copy number profiles that were concordant with matched DNA methylation arrays and confirmed the clonal origin of each metastasis. Malignant metaprograms were organ-associated, with a stress- and hypoxia-associated program enriched in lung metastases and a proliferative, matrix-remodeling program enriched in liver metastases. Antigen-presenting cancer-associated fibroblasts (apCAFs) were enriched in metastases relative to matched primaries. This shift was reproduced in the spatial cohort (p = 0.001), where apCAFs formed a discrete band at the tumor-organ interface between malignant cells and adjacent parenchyma, whereas they were sparse and randomly distributed in primary tumors. Spatial transcriptomics further resolved the malignant compartment into three histomolecular phenotypes: (i) smooth-muscle-like with myxoid features, (ii) GPNMB⁺ with anaplastic features, and (iii) PDGFRB⁺ with vessel-rich stroma, each with a concordant immunohistochemical (α-SMA, GPNMB, PDGFRB) and morphological correlate. Together, our data provide a matched primary-metastasis reference for leiomyosarcoma, identify apCAFs as a spatially organized, metastasis-associated stromal population, and delineate histomolecular phenotypes recognizable by routine immunohistochemistry, including a GPNMB⁺ phenotype potentially amenable to GPNMB-directed therapies.
- Open Access
- 23 July 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (10) , 111999
Variations in surgical strategies and treatment allocation for retroperitoneal sarcomas across German-speaking sarcoma centres
- 23 July 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (10) , 111999
Open AccessVariations in surgical strategies and treatment allocation for retroperitoneal sarcomas across German-speaking sarcoma centres
- Open Access
- 17 April 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 411 (1)
Discrepancies between clinical and radiological assessment of complete remission of rectal cancer after neoadjuvant radiochemotherapy
Aim: The watch & wait concept in rectal cancer offers a promising non-operative strategy for patients who achieve a complete response following neoadjuvant radiochemotherapy (nRCT). However, accurately diagnosing clinical complete remission (cCR) based on clinical examinations, endoscopy and imaging remains a major challenge. Methods: This retrospective study included patients with rectal cancer who received nRCT at the University Hospital Erlangen between May 2022 and July 2024 (radiation: 50.4–54 Gy or 5x5 Gy; chemotherapy: 5-FU and oxaliplatin, partially as part of a total neoadjuvant therapy (TNT) concept). Patients were analyzed based on their clinical, endoscopic, and radiological findings, and classified as having either consistent or discrepant diagnostic results. Particular attention was paid to patients with discrepancies between diagnostic modalities. Results: A total of 78 patients underwent nRCT for rectal cancer during the study period. Six patients were excluded due to a second malignancy, tumor recurrence, or incomplete restaging. 72 patients were included in the final analysis. Of these, 46 patients showed consistent evidence of residual tumor during restaging, leading to surgical resection, with histopathological confirmation of residual tumor in 76% of cases. A clinical and radiological complete remission was observed in 12 of 72 patients (16.7%), four of whom experienced local regrowth. Discrepancies were noted between clinical, endoscopic and radiological findings following nRCT in 14 patients (median age 68 years, range 40–73). Of these patients, 13 had a negative MRI and one had a negative endoscopy, despite differing findings on the other modalities. Conclusion: Diagnosing complete remission after nRCT remains challenging within the context of a watch & wait strategy. Our findings suggest that pelvic MRI may overestimate the response to treatment. This is consistent with published data. Discrepancies between clinical, endoscopic, and radiologic assessments should prompt caution and emphasize the need for individualized decision-making before surgery is omitted.
- 17 April 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 411 (1)
Open AccessDiscrepancies between clinical and radiological assessment of complete remission of rectal cancer after neoadjuvant radiochemotherapy
Aim: The watch & wait concept in rectal cancer offers a promising non-operative strategy for patients who achieve a complete response following neoadjuvant radiochemotherapy (nRCT). However, accurately diagnosing clinical complete remission (cCR) based on clinical examinations, endoscopy and imaging remains a major challenge. Methods: This retrospective study included patients with rectal cancer who received nRCT at the University Hospital Erlangen between May 2022 and July 2024 (radiation: 50.4–54 Gy or 5x5 Gy; chemotherapy: 5-FU and oxaliplatin, partially as part of a total neoadjuvant therapy (TNT) concept). Patients were analyzed based on their clinical, endoscopic, and radiological findings, and classified as having either consistent or discrepant diagnostic results. Particular attention was paid to patients with discrepancies between diagnostic modalities. Results: A total of 78 patients underwent nRCT for rectal cancer during the study period. Six patients were excluded due to a second malignancy, tumor recurrence, or incomplete restaging. 72 patients were included in the final analysis. Of these, 46 patients showed consistent evidence of residual tumor during restaging, leading to surgical resection, with histopathological confirmation of residual tumor in 76% of cases. A clinical and radiological complete remission was observed in 12 of 72 patients (16.7%), four of whom experienced local regrowth. Discrepancies were noted between clinical, endoscopic and radiological findings following nRCT in 14 patients (median age 68 years, range 40–73). Of these patients, 13 had a negative MRI and one had a negative endoscopy, despite differing findings on the other modalities. Conclusion: Diagnosing complete remission after nRCT remains challenging within the context of a watch & wait strategy. Our findings suggest that pelvic MRI may overestimate the response to treatment. This is consistent with published data. Discrepancies between clinical, endoscopic, and radiologic assessments should prompt caution and emphasize the need for individualized decision-making before surgery is omitted.
- Open Access
Prospective Analysis of Multidisciplinary (MDT)-Based Cross-Sectional Imaging to Predict the Histology of Soft Tissue Tumors (BACH-Trial)
Background: The necessity of a pre-therapeutic biopsy for soft tissue tumors is assessed differently depending on imaging. We examined the concordance of histopathological and radiological imaging-based diagnoses of soft tissue tumors in a monocentric, multidisciplinary sarcoma board. Methods: From October 2022 to December 2024, we prospectively included 184 patients presenting with preoperative imaging but without prior histology who are presented at the multidisciplinary sarcoma board of the University Hospital of Erlangen. We evaluated tumor dignity (benign/malignant) and most probable tumor subtype based on cross-sectional imaging assisted by the demographic and anatomic characteristics of individual cases. This assessment was then compared with the final pathological results. Results: We classified 75 tumors as benign and 109 tumors as malignant. Of the 75 patients with a suspected benign tumor, 66 (88%) had a benign diagnosis confirmed by pathological assessment, while two (2.7%) had a malignant tumor and seven (9.3%) an intermediate biology tumor. Of the 109 patients with suspected malignant tumors, 69 (63.3%) had a malignant pathology, while 30 (27.5%) had a benign pathology, and 10 (9.2%) an intermediate tumor. Matching the multidisciplinary sarcoma board’s assessment with the pathological results revealed significant sensitivity and a negative predictive value for malignant tumors, as well as a significant positive predictive value and specificity for benign tumors. Conclusions: The study shows that, despite the high degree of predictability at an experienced sarcoma center, imaging cannot completely replace biopsies and caution should be exercised when deciding against a biopsy. It is emphasized that the decision not to perform a biopsy can only be made in cases where lipomatous tumors appear benign in imaging procedures, and only in an experienced center.
Open AccessProspective Analysis of Multidisciplinary (MDT)-Based Cross-Sectional Imaging to Predict the Histology of Soft Tissue Tumors (BACH-Trial)
Background: The necessity of a pre-therapeutic biopsy for soft tissue tumors is assessed differently depending on imaging. We examined the concordance of histopathological and radiological imaging-based diagnoses of soft tissue tumors in a monocentric, multidisciplinary sarcoma board. Methods: From October 2022 to December 2024, we prospectively included 184 patients presenting with preoperative imaging but without prior histology who are presented at the multidisciplinary sarcoma board of the University Hospital of Erlangen. We evaluated tumor dignity (benign/malignant) and most probable tumor subtype based on cross-sectional imaging assisted by the demographic and anatomic characteristics of individual cases. This assessment was then compared with the final pathological results. Results: We classified 75 tumors as benign and 109 tumors as malignant. Of the 75 patients with a suspected benign tumor, 66 (88%) had a benign diagnosis confirmed by pathological assessment, while two (2.7%) had a malignant tumor and seven (9.3%) an intermediate biology tumor. Of the 109 patients with suspected malignant tumors, 69 (63.3%) had a malignant pathology, while 30 (27.5%) had a benign pathology, and 10 (9.2%) an intermediate tumor. Matching the multidisciplinary sarcoma board’s assessment with the pathological results revealed significant sensitivity and a negative predictive value for malignant tumors, as well as a significant positive predictive value and specificity for benign tumors. Conclusions: The study shows that, despite the high degree of predictability at an experienced sarcoma center, imaging cannot completely replace biopsies and caution should be exercised when deciding against a biopsy. It is emphasized that the decision not to perform a biopsy can only be made in cases where lipomatous tumors appear benign in imaging procedures, and only in an experienced center.
- Open Access
- 14 September 2024
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 409 (1) , 1-11
The management of retrorectal tumors – a single-center analysis of 21 cases and overview of the literature
Aim: Retrorectal tumors are rare and heterogeneous. They are often asymptomatic or present with nonspecific symptoms, making management challenging. This study examines the diagnosis and treatment of retrorectal tumors. Methods: Between 2002 and 2022, 21 patients with retrorectal tumors were treated in our department. We analyzed patient characteristics, diagnosis and treatment modalities retrospectively. Additionally, a literature review (2002–2023, “retrorectal tumors” and “presacral tumors”, 20 or more cases included) was performed. Results: Of the 21 patients (median age 54 years, 62% female), 17 patients (81%) suffered from benign lesions and 4 (19%) from malignant lesions. Symptoms were mostly nonspecific, with pain being the most common (11/21 (52%)). Diagnosis was incidental in eight cases. Magnetic resonance imaging was performed in 20 (95%) and biopsy was obtained in 10 (48%). Twenty patients underwent surgery, mostly via a posterior approach (14/20 (70%)). At a mean follow-up of 42 months (median 10 months, range 1–166 months), the local recurrence rate was 19%. There was no mortality. Our Pubmed search identified 39 publications. Conclusion: Our data confirms the significant heterogeneity of retrorectal tumors, which poses a challenge to management, especially considering the often nonspecific symptoms. Regarding diagnosis and treatment, our data highlights the importance of MRI and surgical resection. In particular a malignancy rate of almost 20% warrants a surgical resection in case of the findings of a retrorectal tumour. A local recurrence rate of 19% supports the need for follow up.
- 14 September 2024
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 409 (1) , 1-11
Open AccessThe management of retrorectal tumors – a single-center analysis of 21 cases and overview of the literature
Aim: Retrorectal tumors are rare and heterogeneous. They are often asymptomatic or present with nonspecific symptoms, making management challenging. This study examines the diagnosis and treatment of retrorectal tumors. Methods: Between 2002 and 2022, 21 patients with retrorectal tumors were treated in our department. We analyzed patient characteristics, diagnosis and treatment modalities retrospectively. Additionally, a literature review (2002–2023, “retrorectal tumors” and “presacral tumors”, 20 or more cases included) was performed. Results: Of the 21 patients (median age 54 years, 62% female), 17 patients (81%) suffered from benign lesions and 4 (19%) from malignant lesions. Symptoms were mostly nonspecific, with pain being the most common (11/21 (52%)). Diagnosis was incidental in eight cases. Magnetic resonance imaging was performed in 20 (95%) and biopsy was obtained in 10 (48%). Twenty patients underwent surgery, mostly via a posterior approach (14/20 (70%)). At a mean follow-up of 42 months (median 10 months, range 1–166 months), the local recurrence rate was 19%. There was no mortality. Our Pubmed search identified 39 publications. Conclusion: Our data confirms the significant heterogeneity of retrorectal tumors, which poses a challenge to management, especially considering the often nonspecific symptoms. Regarding diagnosis and treatment, our data highlights the importance of MRI and surgical resection. In particular a malignancy rate of almost 20% warrants a surgical resection in case of the findings of a retrorectal tumour. A local recurrence rate of 19% supports the need for follow up.
- Open Access
- 23 August 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 50 (12) , 108619
Unraveling the role of local ablative therapies for patients with metastatic soft tissue sarcoma – A retrospective multicenter study of the Bavarian university hospitals
- 23 August 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 50 (12) , 108619
Open AccessUnraveling the role of local ablative therapies for patients with metastatic soft tissue sarcoma – A retrospective multicenter study of the Bavarian university hospitals
- 23 March 2024
- Published by Springer Nature
- p. 289-311
Sarkome und Tumororthopädie
- Open Access
- 30 January 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (2) , 262
Interdisciplinary Surgical Therapy of Extremity Soft-Tissue Sarcomas: A Personalized Resection and Reconstruction Algorithm
Soft-tissue sarcomas (STS) are rare, but potentially life-threatening malignancies. STS can occur anywhere in the human body with the limbs being the most common site. Referral to a specialized sarcoma center is crucial to guarantee prompt and appropriate treatment. STS treatment strategies should be discussed in an interdisciplinary tumor board to involve expertise from all available resources, including an experienced reconstructive surgeon for an optimal outcome. In many cases, extensive resection is needed to achieve R0 resection, resulting in large defects after surgery. Hence, an evaluation of whether plastic reconstruction might be required is mandatory to avoid complications due to insufficient primary wound closure. In this retrospective observational study, we present data of patients with extremity STS treated at the Sarcoma Center, University Hospital Erlangen, in 2021. We found that complications were more frequent in patients who received secondary flap reconstruction after insufficient primary wound closure compared to patients who received primary flap reconstruction. Additionally, we propose an algorithm for an interdisciplinary surgical therapy of soft-tissue sarcomas regarding resection and reconstruction and present two problematic cases to emphasize the complexity of surgical sarcoma therapy.
- 30 January 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (2) , 262
Open AccessInterdisciplinary Surgical Therapy of Extremity Soft-Tissue Sarcomas: A Personalized Resection and Reconstruction Algorithm
Soft-tissue sarcomas (STS) are rare, but potentially life-threatening malignancies. STS can occur anywhere in the human body with the limbs being the most common site. Referral to a specialized sarcoma center is crucial to guarantee prompt and appropriate treatment. STS treatment strategies should be discussed in an interdisciplinary tumor board to involve expertise from all available resources, including an experienced reconstructive surgeon for an optimal outcome. In many cases, extensive resection is needed to achieve R0 resection, resulting in large defects after surgery. Hence, an evaluation of whether plastic reconstruction might be required is mandatory to avoid complications due to insufficient primary wound closure. In this retrospective observational study, we present data of patients with extremity STS treated at the Sarcoma Center, University Hospital Erlangen, in 2021. We found that complications were more frequent in patients who received secondary flap reconstruction after insufficient primary wound closure compared to patients who received primary flap reconstruction. Additionally, we propose an algorithm for an interdisciplinary surgical therapy of soft-tissue sarcomas regarding resection and reconstruction and present two problematic cases to emphasize the complexity of surgical sarcoma therapy.
- Open Access
Long-Term Follow-Up of Patients Receiving Neoadjuvant Treatment Modalties for Soft Tissue Sarcomas of the Extremities
Background: Neoadjuvant treatment modalities in soft tissue sarcoma (STS) of the extremities have become more popular in recent years, but because of the rarity and heterogeneity of STS, there are yet few studies on the long-term impact of neoadjuvant treatment modalities, especially in terms of neoadjuvant radiochemotherapy. Methods: The study enrolled 136 patients with primary STS of the extremities who underwent surgery with curative intent or neoadjuvant therapy, followed by surgery in a 15-year period. Neoadjuvant treatment consisted of radiotherapy (RT) with 60 Gy and in most cases simultaneous chemotherapy (CTx) with ifosfamide (1.5 g/m2/d, d1–5, q28) and doxorubicine (50 mg/m2/d, d3, q28). We investigated the clinical, (post)-operative and histopathological data and the oncological follow-up as well. The median follow-up period was 82 months (range 6–202). Results: A total of 136 patients (M:F = 73:63) with a mean age of 62 years (range; 21–93) was observed. Seventy-four patients (54.4%) received neoadjuvant therapy (NT), 62 patients (45.6%) received primary surgery (PS). When receiving NT, patients with high-risk STS had a lower risk to develop distant metastasis (p = 0.025). Age, histological type, tumor size and surgical margins (R0 vs. R1) had no influence on any survival rates. There was an association between NT and the occurrence of postoperative complications (p = 0.001). The 5-year local recurrence free survival (LRFS), metastasis free survival (MFS), disease free survival (DFS) and overall survival (OS) rate of the whole cohort was 89.9%, 77.0%, 70.6% and 72.6%; whereas the 5-year LRFS, MFS, DFS and OS rate was 90.5%, 67.2%, 64.1% and 62.8% for the NT group and 89.5%, 88.3%. 78.4% and 83.8% for the PS group. Conclusions: Multimodal treatment strategies in patients with STS of extremities lead to excellent oncological outcomes. Patients with high-risk STS had a significantly better MFS when receiving NT than patients with low-risk STS. NT was associated with a higher probability of postoperative but well-manageable complications.
Open AccessLong-Term Follow-Up of Patients Receiving Neoadjuvant Treatment Modalties for Soft Tissue Sarcomas of the Extremities
Background: Neoadjuvant treatment modalities in soft tissue sarcoma (STS) of the extremities have become more popular in recent years, but because of the rarity and heterogeneity of STS, there are yet few studies on the long-term impact of neoadjuvant treatment modalities, especially in terms of neoadjuvant radiochemotherapy. Methods: The study enrolled 136 patients with primary STS of the extremities who underwent surgery with curative intent or neoadjuvant therapy, followed by surgery in a 15-year period. Neoadjuvant treatment consisted of radiotherapy (RT) with 60 Gy and in most cases simultaneous chemotherapy (CTx) with ifosfamide (1.5 g/m2/d, d1–5, q28) and doxorubicine (50 mg/m2/d, d3, q28). We investigated the clinical, (post)-operative and histopathological data and the oncological follow-up as well. The median follow-up period was 82 months (range 6–202). Results: A total of 136 patients (M:F = 73:63) with a mean age of 62 years (range; 21–93) was observed. Seventy-four patients (54.4%) received neoadjuvant therapy (NT), 62 patients (45.6%) received primary surgery (PS). When receiving NT, patients with high-risk STS had a lower risk to develop distant metastasis (p = 0.025). Age, histological type, tumor size and surgical margins (R0 vs. R1) had no influence on any survival rates. There was an association between NT and the occurrence of postoperative complications (p = 0.001). The 5-year local recurrence free survival (LRFS), metastasis free survival (MFS), disease free survival (DFS) and overall survival (OS) rate of the whole cohort was 89.9%, 77.0%, 70.6% and 72.6%; whereas the 5-year LRFS, MFS, DFS and OS rate was 90.5%, 67.2%, 64.1% and 62.8% for the NT group and 89.5%, 88.3%. 78.4% and 83.8% for the PS group. Conclusions: Multimodal treatment strategies in patients with STS of extremities lead to excellent oncological outcomes. Patients with high-risk STS had a significantly better MFS when receiving NT than patients with low-risk STS. NT was associated with a higher probability of postoperative but well-manageable complications.